
---
title: '_超级强化_攻击肿瘤T细胞，以改善癌症免疫治疗'
categories: 
 - 新媒体
 - 科学网
 - 博客
headimg: 'https://cors.zfour.workers.dev/?http://image.sciencenet.cn/home/202203/16/095405fum6u9ruijkufeub.jpg'
author: 科学网
comments: false
date: Wed, 16 Mar 2022 10:01:00 GMT
thumbnail: 'https://cors.zfour.workers.dev/?http://image.sciencenet.cn/home/202203/16/095405fum6u9ruijkufeub.jpg'
---

<div>   
<p style="line-height: 3em;"><span style="font-family: "times new roman"; font-size: 24px;"><span style="font-family: "times new roman";">耶鲁科学家“超级强化”攻击肿瘤</span>T<span style="font-family: "times new roman";">细胞，以改善癌症免疫治疗</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";">诸平</span></p><p style="text-align: center;"><a href="https://scitechdaily.com/yale-scientists-supercharge-tumor-attacking-t-cells-to-improve-cancer-immunotherapy/" target="_blank"><img src="https://cors.zfour.workers.dev/?http://image.sciencenet.cn/home/202203/16/095405fum6u9ruijkufeub.jpg" title alt="Cancer-Cells-Attacked-by-Killer-T-Lymphocytes-777x518.jpg" referrerpolicy="no-referrer"></a><br></p><p style="line-height: 2em; text-align: center;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-family: "times new roman"; font-size: 18px;">Fig. 1 <a href="https://scitechdaily.com/yale-scientists-supercharge-tumor-attacking-t-cells-to-improve-cancer-immunotherapy/" target="_blank">Illustration of cancer cells attacked by T cells.</a></span></span></p><p style="line-height: 2em; text-align: center;"><a href="https://linkinghub.elsevier.com/retrieve/pii/S1550413122000535" target="_blank"><span style="font-size: 18px; font-family: "times new roman";"><img src="https://cors.zfour.workers.dev/?http://image.sciencenet.cn/home/202203/16/095454sg9850ycqk0b150k.jpg" title alt="1-s2.0-S1550413122000535-fx1_lrg (1).jpg" referrerpolicy="no-referrer"></span></a><span style="font-size: 18px; font-family: "times new roman";"><br></span></p><p style="line-height: 2em; text-align: center;"><a href="https://linkinghub.elsevier.com/retrieve/pii/S1550413122000535" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">Fig.2 Graphical abstract</span></a></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";">据美国耶鲁大学（</span><a href="https://scitechdaily.com/tag/yale-university/" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">Yale University</span></a><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">）</span>2022<span style="font-size: 18px; font-family: 宋体;">年</span>3<span style="font-size: 18px; font-family: 宋体;">月</span>14<span style="font-size: 18px; font-family: 宋体;">日提供的消息，耶鲁大学的科学家们发现了一种“超级强化”攻击肿瘤的</span>T<span style="font-size: 18px; font-family: 宋体;">细胞的方法（</span></span><a href="https://scitechdaily.com/yale-scientists-supercharge-tumor-attacking-t-cells-to-improve-cancer-immunotherapy/" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">Yale Scientists “Supercharge” Tumor-Attacking T Cells To Improve Cancer Immunotherapy</span></a><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">），这一发现不仅可能提高一种有前途的基于细胞的癌症免疫疗法的有效性，而且还可能增加它可以治疗的癌症数量。癌细胞被</span>T<span style="font-size: 18px; font-family: 宋体;">细胞攻击的图示见图</span>1<span style="font-size: 18px; font-family: 宋体;">。相关研究结果于</span>2022<span style="font-size: 18px; font-family: 宋体;">年</span>3<span style="font-size: 18px; font-family: 宋体;">月</span>10<span style="font-size: 18px; font-family: 宋体;">日已经在《细胞代谢》（</span></span><a href="https://linkinghub.elsevier.com/retrieve/pii/S1550413122000535" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">Cell Metabolism</span></a><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">）杂志网站发表——</span>Lupeng Ye, Jonathan J. Park, Lei Peng, Quanjun Yang, Ryan D. Chow, Matthew B. Dong, Stanley Z. Lam, Jianjian Guo, Erting Tang, Yueqi Zhang, Guangchuan Wang, Xiaoyun Dai, Yaying Du, Hyunu R. Kim, Hanbing Cao, Youssef Errami, Paul Clark, Alexey Bersenev, Ruth R. Montgomery, Sidi Chen. A genome-scale gain-of-function CRISPR screen in CD8 T cells identifies proline metabolism as a means to enhance CAR-T therapy. </span><a href="https://linkinghub.elsevier.com/retrieve/pii/S1550413122000535" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">Cell Metabolism</span></a><span style="font-size: 18px; font-family: "times new roman";">, Available online 10 March 2022. </span><a href="https://doi.org/10.1016/j.cmet.2022.02.009" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">DOI: 10.1016/j.cmet.2022.02.009</span></a><span style="font-size: 18px; font-family: "times new roman";">. </span><a href="https://linkinghub.elsevier.com/retrieve/pii/S1550413122000535" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">https://linkinghub.elsevier.com/retrieve/pii/S1550413122000535</span></a></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">这一发现可以推进</span>CAR-T<span style="font-size: 18px; font-family: 宋体;">细胞疗法（</span>CAR-T cell therapy<span style="font-size: 18px; font-family: 宋体;">），通过将肿瘤检测分子引入细胞，利用</span>T<span style="font-size: 18px; font-family: 宋体;">细胞对癌症的免疫反应产生动力。在过去的十年里，美国食品和药物管理局（</span>U.S. Food and Drug Administration<span style="font-size: 18px; font-family: 宋体;">）已经批准了</span>6<span style="font-size: 18px; font-family: 宋体;">种</span>CAR-T<span style="font-size: 18px; font-family: 宋体;">细胞疗法来治疗</span>B<span style="font-size: 18px; font-family: 宋体;">细胞淋巴瘤（</span>B cell lymphomas<span style="font-size: 18px; font-family: 宋体;">）和多发性骨髓瘤（</span>multiple myeloma<span style="font-size: 18px; font-family: 宋体;">）。但是，尽管早期取得了成功，这种治疗的有效性往往会随着时间的推移而减弱，这就促使人们开始寻找增强</span>T<span style="font-size: 18px; font-family: 宋体;">细胞功能的方法。</span></span><span style="font-size: 18px; font-family: 宋体;">此外，目前还尚未批准来治疗实体肿瘤</span><span style="font-family: "times new roman"; font-size: 18px;">CAR-T</span><span style="font-size: 18px; font-family: 宋体;">细胞疗法。</span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">在这项新研究中，耶鲁大学遗传学副教授、此论文的通讯作者陈思弟（</span>Sidi Chen<span style="font-size: 18px; font-family: 宋体;">音译）实验室的研究人员设计了一种巧妙的方法，可以有效扫描</span>CD8 T<span style="font-size: 18px; font-family: 宋体;">细胞的基因组，寻找可能增强此细胞攻击癌细胞能力的特定基因。</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">“我们开发了一种新的全基因组功能筛选，以发现一种分子酶，它的作用就像脚踩油门一样，可以增加</span>T<span style="font-size: 18px; font-family: 宋体;">细胞的代谢活性，”陈思弟说。</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">他们发现，在用于研究</span>3<span style="font-size: 18px; font-family: 宋体;">种不同类型癌症</span>(<span style="font-size: 18px; font-family: 宋体;">包括固体肿瘤乳腺癌</span>)<span style="font-size: 18px; font-family: 宋体;">的小鼠模型中，包括</span>PRODH2(<span style="font-size: 18px; font-family: 宋体;">一种参与细胞代谢的基因</span>)<span style="font-size: 18px; font-family: 宋体;">在内的几个基因的高水平活性刺激了</span>CAR-T<span style="font-size: 18px; font-family: 宋体;">细胞活性的增加。研究人员说，研究结果表明，有可能产生超代谢的</span>CAR-T<span style="font-size: 18px; font-family: 宋体;">细胞，其性能超过现有的细胞疗法。</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">陈思弟说，利用这些系统和发现，未来的研究可以在临床环境中测试新识别的代谢增强</span>CAR -Ts<span style="font-size: 18px; font-family: 宋体;">细胞类型，以识别其它</span>T<span style="font-size: 18px; font-family: 宋体;">细胞超级充能器（</span>T cell super-chargers<span style="font-size: 18px; font-family: 宋体;">），并将基于细胞的免疫治疗扩展到不同类型的癌症，特别是实体肿瘤。</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">陈思弟教授隶属于耶鲁大学癌症中心（</span>Yale Cancer Center<span style="font-size: 18px; font-family: 宋体;">）、耶鲁干细胞中心（</span>Yale Stem Cell Center<span style="font-size: 18px; font-family: 宋体;">）、耶鲁大学生物医学数据科学中心（</span>Yale Center for Biomedical Data Science<span style="font-size: 18px; font-family: 宋体;">）、系统生物学研究所（</span>Systems Biology Institute<span style="font-size: 18px; font-family: 宋体;">）和耶鲁大学西校区癌症系统生物学中心（</span>Center for Cancer Systems Biology at Yale’s West Campus<span style="font-size: 18px; font-family: 宋体;">）。</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">耶鲁大学的叶鲁鹏（</span>Lupeng Ye<span style="font-size: 18px; font-family: 宋体;">音译）、乔纳森·帕克（</span>Jonathan Park<span style="font-size: 18px; font-family: 宋体;">）、彭磊（</span>Lei Peng音译<span style="font-size: 18px; font-family: 宋体;">）和杨全军（</span>Quanjun Yang音译<span style="font-size: 18px; font-family: 宋体;">）是上述论文的共同第一作者。这项研究主要由美国国立卫生研究院（</span>National Institutes of Health<span style="font-size: 18px; font-family: 宋体;">）和美国国防部（</span>U.S. Department of Defense<span style="font-size: 18px; font-family: 宋体;">）资助。</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";">上述介绍，仅供参考。欲了解更多信息，敬请注意浏览</span><a href="https://linkinghub.elsevier.com/retrieve/pii/S1550413122000535" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">原文</span></a><span style="font-size: 18px; font-family: "times new roman";">或者</span><a href="https://scitechdaily.com/yale-scientists-supercharge-tumor-attacking-t-cells-to-improve-cancer-immunotherapy/" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">相关报道</span></a><span style="font-size: 18px; font-family: "times new roman";">。</span></p><p style="line-height: 2em;"><a href="https://linkinghub.elsevier.com/retrieve/pii/S1550413122000535" style="text-decoration: underline; font-size: 18px; font-family: "arial black", "avant garde";" target="_blank"><span style="font-size: 18px; font-family: "arial black", "avant garde";">Highlights</span></a></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";">• Dead-guide RNA-based CRISPR activation screen identifies targets for CAR-T engineering</span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";">• <em>PRODH2</em> gain of function reprograms proline metabolism in CD8<sup>+</sup> T cells</span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";">• <em>PRODH2</em> reshapes transcriptome, metabolome, and immune functions in CAR-T cells</span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";">• <em>PRODH2</em> reprogramming enhances CAR-T cell therapy in both <em>in vitro</em> and <em>in vivo</em> settings</span></p><p style="line-height: 2em;"><a href="https://linkinghub.elsevier.com/retrieve/pii/S1550413122000535" style="text-decoration: underline; font-size: 18px; font-family: "arial black", "avant garde";" target="_blank"><span style="font-size: 18px; font-family: "arial black", "avant garde";">Summary</span></a></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";">Chimeric antigen receptor (CAR)-T cell-based immunotherapy for cancer and immunological diseases has made great strides, but it still faces multiple hurdles. Finding the right molecular targets to engineer T cells toward a desired function has broad implications for the armamentarium of T cell-centered therapies. Here, we developed a dead-guide RNA (dgRNA)-based CRISPR activation screen in primary CD8<sup>+</sup> T cells and identified gain-of-function (GOF) targets for CAR-T engineering. Targeted knockin or overexpression of a lead target, <em>PRODH2</em>, enhanced CAR-T-based killing and <em>in vivo</em> efficacy in multiple cancer models. Transcriptomics and metabolomics in CAR-T cells revealed that augmenting <em>PRODH2</em> expression reshaped broad and distinct gene expression and metabolic programs. Mitochondrial, metabolic, and immunological analyses showed that <em>PRODH2</em> engineering enhances the metabolic and immune functions of CAR-T cells against cancer. Together, these findings provide a system for identification of GOF immune boosters and demonstrate <em>PRODH2</em> as a target to enhance CAR-T efficacy.</span></p>                    <br><br>
                                        <label style="font-size:13px; color:#850f0f">转载本文请联系原作者获取授权，同时请注明本文来自诸平科学网博客。<br>链接地址：</label><a href="https://blog.sciencenet.cn/blog-212210-1329631.html" target="_blank" style="font-size:13px; color:#850f0f">https://blog.sciencenet.cn/blog-212210-1329631.html </a>
  <br><br>上一篇：<a href="http://blog.sciencenet.cn/blog-212210-1329541.html" target="_black">抗衰老突破：细胞再生疗法安全逆转小鼠衰老过程</a><br>下一篇：<a href="http://blog.sciencenet.cn/blog-212210-1329705.html" target="_black">服用他汀类药物的益处受到质疑:高胆固醇和心脏病之间的联系“不一致”</a>                    <!--大赛结束-->
                                        
  
</div>
            